1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Weiss, M.A. Hua, Q.X. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US J.Biol.Chem. JBCHA3 0071 0021-9258 279 21449 21460 10.1074/jbc.M314141200 14988398 Mechanism of insulin fibrillation: the structure of insulin under amyloidogenic conditions resembles a protein-folding intermediate 2004 10.2210/pdb1sf1/pdb pdb_00001sf1 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 2383.698 INSULIN A CHAIN 1 man polymer 3433.953 Insulin 1 man polymer no no GIVEQCCTSICSLYQLENYCN GIVEQCCTSICSLYQLENYCN A polypeptide(L) no no FVNQHLCGSHLVEALYLVCGERGFFYTPKT FVNQHLCGSHLVEALYLVCGERGFFYTPKT B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo Escherichia sample 9606 Homo sapiens 562 Escherichia coli human Homo Escherichia sample INS 9606 Homo sapiens 562 Escherichia coli database_2 pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 2004-03-30 1 1 2008-04-29 1 2 2011-07-13 1 3 2022-03-02 _database_2.pdbx_DOI _database_2.pdbx_database_accession NMR Structure Of Human Insulin In 20% Acetic Acid, Zinc-Free, 10 Structures: Native human insulin at 25 degree, NMR solution structure RCSB Y RCSB 2004-02-19 REL REL THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR AND 15N-3D HETERONUCLEAR NMR TECHNIQUES. structures with the lowest energy 40 15 2D TOCSY NOESY COSY 3D_15N-separated_NOESY 2.4 ambient 333 K RMSD VALUES FOR ALL 15 STRUCTURES VERSUS GEOMETRIC AVERAGE: (BACKBONE, A2-A20, B4-B24) 2.27 ANGSTROM DISTANCE GEOMETRY AND SIMULATED ANNEALING 1 closest to the average 0.5 mM 15N-labeled sample pH 2.4 and 60C, 90% H2O/10%D2O BRUNGER refinement X-PLOR 2.1 Varian structure solution VNMR 6.1B 6.1B 800 Bruker DRX 600 Varian INOVA GLY 1 n 1 GLY 1 A ILE 2 n 2 ILE 2 A VAL 3 n 3 VAL 3 A GLU 4 n 4 GLU 4 A GLN 5 n 5 GLN 5 A CYS 6 n 6 CYS 6 A CYS 7 n 7 CYS 7 A THR 8 n 8 THR 8 A SER 9 n 9 SER 9 A ILE 10 n 10 ILE 10 A CYS 11 n 11 CYS 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A GLN 15 n 15 GLN 15 A LEU 16 n 16 LEU 16 A GLU 17 n 17 GLU 17 A ASN 18 n 18 ASN 18 A TYR 19 n 19 TYR 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A PHE 1 n 1 PHE 1 B VAL 2 n 2 VAL 2 B ASN 3 n 3 ASN 3 B GLN 4 n 4 GLN 4 B HIS 5 n 5 HIS 5 B LEU 6 n 6 LEU 6 B CYS 7 n 7 CYS 7 B GLY 8 n 8 GLY 8 B SER 9 n 9 SER 9 B HIS 10 n 10 HIS 10 B LEU 11 n 11 LEU 11 B VAL 12 n 12 VAL 12 B GLU 13 n 13 GLU 13 B ALA 14 n 14 ALA 14 B LEU 15 n 15 LEU 15 B TYR 16 n 16 TYR 16 B LEU 17 n 17 LEU 17 B VAL 18 n 18 VAL 18 B CYS 19 n 19 CYS 19 B GLY 20 n 20 GLY 20 B GLU 21 n 21 GLU 21 B ARG 22 n 22 ARG 22 B GLY 23 n 23 GLY 23 B PHE 24 n 24 PHE 24 B PHE 25 n 25 PHE 25 B TYR 26 n 26 TYR 26 B THR 27 n 27 THR 27 B PRO 28 n 28 PRO 28 B LYS 29 n 29 LYS 29 B THR 30 n 30 THR 30 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 5 B B O H HIS CYS 5 7 1.52 5 B B O H GLU TYR 13 16 1.55 6 B B O H CYS GLY 19 23 1.47 1 B ARG 22 0.222 SIDE CHAIN 2 B ARG 22 0.316 SIDE CHAIN 3 B ARG 22 0.314 SIDE CHAIN 4 B ARG 22 0.248 SIDE CHAIN 5 B ARG 22 0.279 SIDE CHAIN 6 B ARG 22 0.318 SIDE CHAIN 7 B ARG 22 0.166 SIDE CHAIN 8 B ARG 22 0.260 SIDE CHAIN 9 B ARG 22 0.313 SIDE CHAIN 10 B ARG 22 0.293 SIDE CHAIN 11 B ARG 22 0.293 SIDE CHAIN 12 B ARG 22 0.317 SIDE CHAIN 13 B ARG 22 0.312 SIDE CHAIN 14 B ARG 22 0.298 SIDE CHAIN 15 B ARG 22 0.230 SIDE CHAIN 1 -32.05 2.10 120.10 88.05 A A A CA C O ASN ASN ASN 21 21 21 N 13 -20.47 2.10 120.10 99.63 A A A CA C O ASN ASN ASN 21 21 21 N 4 A A C O ASN ASN 21 21 0.161 0.019 1.229 1.390 N 13 A A C O ASN ASN 21 21 0.200 0.019 1.229 1.429 N 1 A THR 8 161.65 44.83 1 A SER 9 161.27 106.14 1 A ILE 10 82.09 177.37 1 A CYS 11 73.91 122.36 1 A SER 12 169.30 61.66 1 A LEU 13 62.91 87.74 1 A TYR 14 164.98 -51.14 1 A LEU 16 -70.28 -125.71 1 A GLU 17 46.19 26.17 1 A ASN 18 175.15 30.83 1 B CYS 7 53.61 -177.66 1 B PHE 25 -73.64 -74.32 2 A GLU 4 68.55 83.08 2 A GLN 5 176.03 130.35 2 A CYS 6 -42.78 -83.68 2 A THR 8 176.70 60.33 2 A SER 9 -171.37 25.53 2 A ILE 10 52.38 110.00 2 A CYS 20 -157.89 77.51 2 B ASN 3 -174.97 65.31 2 B CYS 7 162.61 48.58 2 B GLU 21 64.89 -173.04 2 B ARG 22 75.24 67.32 2 B PHE 24 67.44 138.37 2 B PHE 25 178.32 -68.36 2 B THR 27 61.81 146.45 3 A GLU 4 -126.52 -129.01 3 A GLN 5 -56.16 -91.44 3 A CYS 6 161.88 101.89 3 A CYS 7 -159.50 -36.05 3 A SER 9 163.69 -77.09 3 A CYS 11 -153.05 81.92 3 A LEU 16 -79.86 -119.96 3 A GLU 17 44.67 27.52 3 A ASN 18 -171.38 35.53 3 B ASN 3 -54.88 -175.46 3 B GLN 4 -91.66 53.74 3 B LEU 6 -114.94 -164.31 3 B CYS 7 60.12 -169.41 3 B SER 9 78.17 -3.32 3 B GLU 13 -100.59 -72.92 3 B GLU 21 60.98 -86.98 3 B TYR 26 -123.63 -126.74 4 A ILE 2 -93.52 48.93 4 A GLU 4 -159.57 55.65 4 A GLN 5 -148.10 -33.81 4 A CYS 6 67.76 92.00 4 A CYS 7 -159.98 -34.02 4 A SER 9 171.06 -56.99 4 A ILE 10 164.93 127.31 4 A LEU 16 -69.76 -110.58 4 A GLU 17 43.73 29.60 4 A ASN 18 -164.30 -32.80 4 A CYS 20 -173.06 83.85 4 B VAL 2 -147.25 51.84 4 B HIS 5 30.21 56.38 4 B LEU 6 -112.95 -167.92 4 B CYS 7 60.95 -171.97 4 B SER 9 78.27 -2.76 4 B GLU 13 -67.91 -78.50 4 B GLU 21 46.87 75.43 4 B PHE 25 -74.76 -72.05 4 B TYR 26 66.20 68.72 4 B THR 27 46.28 92.88 4 B LYS 29 56.78 -171.21 5 A GLU 4 -175.48 72.15 5 A THR 8 173.22 -30.42 5 A SER 9 116.66 58.54 5 A ILE 10 -162.25 84.44 5 A CYS 11 178.27 70.29 5 A LEU 16 -69.59 -119.20 5 A GLU 17 45.17 26.70 5 A ASN 18 -167.87 24.15 5 A CYS 20 -164.23 48.32 5 B ASN 3 179.89 107.78 5 B GLN 4 56.63 83.76 5 B HIS 5 -43.60 151.46 5 B LEU 6 -60.92 50.49 5 B CYS 7 -159.49 73.69 5 B GLU 13 -59.59 -80.57 5 B LEU 17 177.83 -32.83 5 B GLU 21 -40.01 95.58 5 B ARG 22 179.16 -43.60 5 B PHE 25 -57.07 91.01 5 B THR 27 178.39 134.02 5 B LYS 29 -135.36 -81.08 6 A ILE 2 178.92 139.02 6 A VAL 3 -59.08 170.61 6 A GLU 4 -128.26 -126.24 6 A GLN 5 161.58 -172.24 6 A CYS 6 -48.35 -87.35 6 A CYS 7 -121.36 -60.89 6 A THR 8 174.63 86.23 6 A SER 9 166.32 -64.99 6 A ILE 10 178.16 144.01 6 A CYS 11 -151.71 64.38 6 A LEU 16 -70.83 -126.38 6 A GLU 17 45.55 26.78 6 A ASN 18 174.56 -88.87 6 A CYS 20 -145.60 56.43 6 B HIS 5 -178.27 113.76 6 B CYS 7 35.29 54.88 6 B GLU 13 -52.51 -72.65 6 B ARG 22 -130.53 -36.65 6 B PHE 25 -178.80 31.72 6 B THR 27 173.06 99.55 6 B LYS 29 50.41 -171.85 7 A ILE 2 41.69 -169.20 7 A GLU 4 -175.70 51.07 7 A GLN 5 -163.53 96.59 7 A CYS 6 -59.84 -92.50 7 A THR 8 163.39 32.38 7 A SER 9 157.01 -85.41 7 A CYS 11 149.59 68.43 7 A SER 12 -103.17 45.46 7 A TYR 14 -149.61 -69.81 7 A LEU 16 -74.88 -116.36 7 A GLU 17 41.27 29.22 7 A ASN 18 167.02 -64.07 7 A TYR 19 46.72 26.22 7 B GLN 4 60.88 68.14 7 B GLU 13 -50.16 -75.70 7 B PHE 25 -179.48 74.65 7 B TYR 26 179.83 46.14 8 A GLU 4 -163.45 47.35 8 A CYS 7 -151.18 12.94 8 A THR 8 -158.43 23.47 8 A SER 9 161.72 37.72 8 A ILE 10 55.67 165.60 8 A SER 12 56.22 164.40 8 A GLN 15 -91.86 -69.41 8 A LEU 16 -62.11 -140.54 8 A GLU 17 48.02 22.58 8 A ASN 18 158.35 31.06 8 A CYS 20 -145.71 -96.17 8 B ASN 3 -177.16 -174.32 8 B GLN 4 -162.25 55.83 8 B CYS 7 39.57 -168.23 8 B GLU 13 -52.00 -70.62 8 B ARG 22 33.65 49.62 8 B PHE 25 35.24 -114.44 8 B TYR 26 166.21 49.21 8 B LYS 29 -169.89 107.22 9 A VAL 3 -62.35 -172.39 9 A GLU 4 66.19 72.95 9 A GLN 5 -55.15 -164.25 9 A CYS 7 -133.95 -38.82 9 A THR 8 -117.66 58.34 9 A SER 9 173.17 -81.42 9 A ILE 10 177.45 154.70 9 A CYS 11 -171.18 87.04 9 A SER 12 -113.45 65.33 9 A LEU 13 76.92 -48.55 9 A LEU 16 -68.93 -122.77 9 A GLU 17 42.89 27.54 9 A ASN 18 167.95 38.09 9 B ASN 3 54.38 100.55 9 B GLN 4 -105.68 51.35 9 B CYS 7 43.62 -168.44 9 B SER 9 77.31 -3.26 9 B ARG 22 -135.50 -153.88 9 B PHE 24 59.90 85.39 9 B PHE 25 -99.99 -94.40 9 B TYR 26 161.94 57.03 9 B THR 27 -165.38 95.05 10 A GLU 4 77.48 49.18 10 A GLN 5 -162.59 18.41 10 A THR 8 178.84 29.72 10 A LEU 16 -79.49 -124.76 10 A GLU 17 45.98 25.91 10 A ASN 18 179.38 29.49 10 A CYS 20 175.59 -29.64 10 B VAL 2 44.92 82.60 10 B ASN 3 179.61 89.35 10 B GLN 4 -94.91 54.20 10 B LEU 6 -41.88 165.56 10 B CYS 7 37.10 94.73 10 B HIS 10 -102.45 -63.93 10 B GLU 21 161.81 -38.60 10 B ARG 22 -65.78 -167.91 10 B PHE 24 -171.65 147.67 10 B THR 27 -171.38 71.65 11 A GLU 4 77.48 49.18 11 A GLN 5 -162.59 18.41 11 A THR 8 178.84 29.72 11 A LEU 16 -79.49 -124.76 11 A GLU 17 45.98 25.91 11 A ASN 18 179.38 29.49 11 A CYS 20 175.59 -29.64 11 B VAL 2 44.92 82.60 11 B ASN 3 179.61 89.35 11 B GLN 4 -94.91 54.20 11 B LEU 6 -41.88 165.56 11 B CYS 7 37.10 94.73 11 B HIS 10 -102.45 -63.93 11 B GLU 21 161.81 -38.60 11 B ARG 22 -65.78 -167.91 11 B PHE 24 -171.65 147.67 11 B THR 27 -171.38 71.65 12 A VAL 3 -56.70 179.86 12 A GLU 4 69.45 85.50 12 A CYS 6 -153.69 -108.40 12 A CYS 7 -98.63 -72.41 12 A THR 8 166.26 34.39 12 A SER 9 158.03 -48.25 12 A CYS 11 161.39 50.70 12 A GLN 15 -106.05 -70.53 12 A LEU 16 -61.71 -142.72 12 A GLU 17 55.84 19.29 12 A ASN 18 165.99 39.45 12 A CYS 20 -147.98 -95.77 12 B VAL 2 60.53 115.39 12 B GLN 4 174.76 86.53 12 B LEU 6 79.29 154.61 12 B SER 9 145.12 -7.19 12 B ARG 22 -46.70 -73.60 13 A ILE 2 -114.29 63.44 13 A GLU 4 -165.63 75.90 13 A GLN 5 177.98 -142.30 13 A CYS 6 -163.15 -98.32 13 A THR 8 174.21 74.05 13 A SER 9 169.18 31.33 13 A ILE 10 58.85 145.95 13 A CYS 11 -159.65 60.62 13 A ASN 18 -148.39 55.67 13 A CYS 20 -72.85 -74.92 13 B GLN 4 177.60 76.39 13 B HIS 5 55.25 80.32 13 B LEU 6 -46.38 172.36 13 B CYS 7 57.25 107.15 13 B SER 9 -170.58 -60.74 13 B CYS 19 -94.07 -64.75 13 B GLU 21 -165.82 -168.50 13 B ARG 22 -52.48 176.07 13 B PHE 25 53.46 -92.48 13 B TYR 26 43.89 71.74 13 B THR 27 -48.70 150.24 14 A THR 8 -171.77 59.11 14 A SER 9 162.65 50.87 14 A ILE 10 47.47 -176.52 14 A CYS 11 -152.33 62.56 14 A LEU 16 -75.45 -123.82 14 A GLU 17 44.74 27.97 14 A ASN 18 173.44 100.22 14 A TYR 19 -179.76 39.22 14 A CYS 20 -174.18 36.57 14 B VAL 2 64.15 94.98 14 B LEU 6 -165.82 62.49 14 B CYS 7 -108.27 55.23 14 B GLU 13 -53.75 -70.62 14 B PHE 24 176.99 132.52 14 B PHE 25 -146.10 17.88 14 B TYR 26 43.82 74.00 15 A GLU 4 -176.16 86.88 15 A GLN 5 177.47 -165.11 15 A CYS 6 -90.96 -104.26 15 A CYS 7 -93.69 -64.30 15 A THR 8 -174.86 85.78 15 A SER 9 164.90 58.57 15 A ILE 10 62.03 147.33 15 A CYS 11 172.44 47.95 15 A LEU 13 -45.12 -74.49 15 A GLN 15 84.59 -17.22 15 A LEU 16 -106.78 -129.61 15 A GLU 17 44.45 26.66 15 A ASN 18 176.40 -79.86 15 B GLN 4 42.85 75.35 15 B HIS 5 179.20 97.20 15 B CYS 7 55.21 -178.46 15 B SER 9 54.53 19.17 15 B GLU 13 -46.00 -73.63 15 B GLU 21 63.04 139.29 15 B ARG 22 170.48 -37.51 15 B PHE 24 41.36 85.03 NMR STRUCTURE OF HUMAN INSULIN under Amyloidogenic Condition, 15 STRUCTURES 1 N N 2 N N A TYR 14 A TYR 14 HELX_P A TYR 19 A TYR 19 1 1 6 B SER 9 B SER 9 HELX_P B CYS 19 B CYS 19 1 2 11 disulf 2.021 A CYS 6 A SG CYS 6 1_555 A CYS 11 A SG CYS 11 1_555 disulf 2.020 A CYS 7 A SG CYS 7 1_555 B CYS 7 B SG CYS 7 1_555 disulf 2.020 A CYS 20 A SG CYS 20 1_555 B CYS 19 B SG CYS 19 1_555 HORMONE/GROWTH FACTOR HORMONE, HUMAN INSULIN, HORMONE-GROWTH FACTOR COMPLEX INS_HUMAN UNP 1 90 P01308 GIVEQCCTSICSLYQLENYCN INS_HUMAN UNP 2 25 P01308 FVNQHLCGSHLVEALYLVCGERGFFYTPKT 90 110 1SF1 1 21 P01308 A 1 1 21 25 54 1SF1 1 30 P01308 B 2 1 30 1 P 1